NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
5/8 — Partial
XPHOZAH (tenapanor) by Ardelyx. Approved for hyperphosphatemia, chronic kidney disease, irritable bowel syndrome with constipation. First approved in 2023.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XPHOZAH (tenapanor) is an oral small-molecule NDA-approved in October 2023 by Ardelyx for multiple indications including hyperphosphatemia in chronic kidney disease, irritable bowel syndrome with constipation, chronic idiopathic constipation, cystic fibrosis, and Parkinson's disease. The mechanism of action involves modulation of intestinal ion transport to reduce phosphate absorption and promote bowel transit. It represents a novel non-systemic approach to treating electrolyte imbalances and GI motility disorders.
$0.001BPart D
Growth16.6 years to LOEEarly commercial phase with minimal market penetration; small team likely focused on market access, reimbursement infrastructure, and indication-specific sales force expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on XPHOZAH at Ardelyx? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.